与ANO3相关的震性 dystonia:病例报告
Mert Altıntaş1, Miraç Yıldırım2, Ece Eker3
1Department of Pediatric Neurology, Ankara University Faculty of Medicine, Ankara, Turkey. mertaltintas@ankara.edu.tr.
Acta neurologica Belgica
|December 24, 2025
概括
一个年轻女性的ANO3基因的一个遗传变异导致了 dystonia (DYT-ANO3),呈现为震和非自愿的. 这一发现扩大了对ANO3相关运动障碍的理解.
科学领域:
- 遗传学和神经学 遗传学和神经学
- 运动障碍 运动障碍
- 神经遗传学 神经遗传学
背景情况:
- 腹痛是一种运动障碍,其特征是肌肉不自发的收缩.
- 与ANO3相关的 dystonia (DYT-ANO3) 是一种罕见的遗传疾病,与ANO3基因的变异有关.
- DYT-ANO3的表型谱很广泛,发病和临床表现各不相同.
研究的目的:
- 报告一个年轻女子被诊断患有DYT-ANO3.3的病例.
- 要突出与ANO3相关的 dystonia 的遗传基础和临床特征.
- 为了解DYT-ANO3.3中的基因型-表型相关性做出贡献.
主要方法:
- 一个21岁的妇女的临床病例介绍,她患有和.
- 神经学检查评估运动症状和认知功能.
- 外体序列测序以确定运动障碍的遗传原因.
主要成果:
- 这位患者一生都患有渐进性震和 dystonia 的病史.
- 外体序列测定在ANO3基因 (c.1943A>G) 中发现了一种可能的致病性异构体变异.
- 该患者被诊断为DYT-ANO3患者,并显示了部分改善与trihexyphenidyl.
结论:
- 这种病例扩大了已知的ANO3相关的临床光谱.
- 这些发现强调了基因测试在诊断运动障碍方面的重要性.
- 需要进一步的研究来澄清DYT-ANO3.3中的基因型-表型相关性.
相关概念视频
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.4K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.4K
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Skeletal Muscle Relaxants: Adverse Effects
751
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
751
Classification of Skeletal Muscle Relaxants
3.0K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.0K


